New hope for breast cancer patients: drug combo aims to prevent return
Disease control
Recruiting now
This study tests whether adding the drug ribociclib to standard hormone therapy can prevent breast cancer from returning in people whose cancer came back in the same area (locoregional recurrence). About 200 adults with hormone receptor-positive, HER2-negative breast cancer will …
Phase: PHASE2 • Sponsor: Oana Danciu • Aim: Disease control
Last updated May 01, 2026 16:00 UTC